Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Norman Nagl, PhD
Articles
5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors
Claudio Faria, PharmD, MPH;Xuan Li, MS;Norman Nagl, PhD;Russell L. Knoth, PhD;Ali McBride, PharmD, MS
May 15th 2015Palonosetron has been found to be effective in treating chemotherapy-induced nausea and vomiting, but no other studies that have compared it with the other 5-HT3 RAs are currently available.
Read More
Latest Updated Articles
Published: June 12th 2025 | Updated: June 16th 2025
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 10th 2025 | Updated: June 12th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 2nd 2025 | Updated: June 11th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 3rd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: May 30th 2025 | Updated: June 5th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: April 18th 2025 | Updated: April 21st 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
